A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in
Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of
ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or
B-cell NHL